Clinical Trial Update: PR1 Vaccination in Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 trial of PR1 Vaccination for leukemia and myelodysplastic syndrome was terminated; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• PR1 Vaccination (PR1 peptide vaccine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2011-04-12